Emestop (ramosetron hydrochloride) / Samyang Group - LARVOL DELTA

Effectiveness of a 5-Hydroxytryptamine Type 3 Receptor Antagonist for Treating Nintedanib-Induced Diarrhea: A Prospective Observational Study. (PubMed, J Clin Med) - " Between October 2022 and March 2025, we enrolled patients with severe nintedanib-induced diarrhea that was uncontrolled by loperamide and/or probiotics. No prominent adverse events were associated with ramosetron administration. Ramosetron, a 5-HT3 antagonist, improved stool frequency and stool form in patients with severe nintedanib-induced diarrhea."

Journal • Observational data • Fibrosis • Gastrointestinal Disorder • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

The Safety and Efficacy of Ramosetron versus Psyllium for the Treatment of Fecal Incontinence (SERAFI): Study protocol for a randomized, parallel, non-inferiority trial. (PubMed, Trials) - P2/3 | "It is believed that 5-HT3 receptor antagonists, along with Psyllium, can improve bowel habits and alleviate symptoms, thereby enhancing the quality of life for patients with FI."

Head-to-Head • Journal • Constipation

Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells. (PubMed, Int J Mol Sci) - "This study aimed to evaluate the effect of 5-HT3 receptor antagonists (ondansetron, palonosetron, and ramosetron) on cancer cell growth using AGS and MKN-1 cell lines, as well as the xenograft mouse model. These findings suggest that 5-HT3 receptor antagonists, especially palonosetron, exert anti-tumor effects in gastric cancer through G1 cell cycle regulation and immunomodulation. The results position palonosetron as a promising lead for further preclinical development in gastric cancer."

Journal • Gastric Cancer • Immunology • Oncology • Solid Tumor • IL1B • IL6 • TNFA • TP53

Pharmacotherapy for fecal incontinence: potential treatment with a traditional Japanese medicine Kampo. (PubMed, Ann Coloproctol) - "Strongly recommended treatments include the antidiarrheal agent loperamide and stool bulking or solidifying agents, such as dietary fiber and polycarbophil. Other therapeutic options include ramosetron, a 5-HT3 receptor antagonist; amitriptyline, a tricyclic antidepressant; and sodium valproate and diazepam, which are GABAergic neuromodulators. Recently, research has explored the efficacy and mechanism of action of DKT, a traditional Japanese medicine Kampo. Historically used for abdominal symptoms like bloating and known for promoting intestinal motility, emerging evidence suggests DKT may also effectively manage FI."

Journal • Review

Ramosetron as a Supportive Agent to Continue Nintedanib in Patients with Interstitial Lung Disease. (PubMed, Intern Med) - "The selective use of ramosetron may improve adherence to nintedanib treatment. However, prospective studies are required to validate these findings."

Journal • Gastrointestinal Disorder • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial. (PubMed, BMC Anesthesiol) - P=N/A | "Low-dose remimazolam infusion did not reduce the incidence of PONV at postoperative 24 h. It was associated with a lower incidence of nausea at postoperative 6 h and dizziness in the PACU."

Clinical • Journal • Anesthesia • Pain

The effects of oxycodone and sufentanil postoperative analgesia on postoperative delirium after thoracoscopic lobectomy: a prospective, randomized controlled study (ChiCTR) - P4 | N=148 | Recruiting | Sponsor: Jianyang People's Hospital; Jianyang People's Hospital

New P4 trial • CNS Disorders

Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity via Decreased Phosphorylation of p38. (PubMed, Biol Pharm Bull) - "Recently, we demonstrated that the incidence of CDDP-induced nephrotoxicity was significantly lower in patients receiving palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA), than in those receiving other 5-HT3RAs (ondansetron, ramosetron, and granisetron). Thus, these findings suggest that concomitant treatment with palonosetron reduces CDDP-induced cytotoxicity by inhibiting p38 phosphorylation, but does not inhibit the hOCT2-mediated transport of CDDP. The present findings provide novel insights into the reduction of CDDP-induced cytotoxicity through concomitant palonosetron treatment."

Journal

Effect of esketamine on sleep quality in elderly patients undergoing knee arthroplasty surgery (ChiCTR) - P4 | N=66 | Completed | Sponsor: The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University

New P4 trial • CNS Disorders • Orthopedics • Sleep Disorder

Comparison of ramosetron with different doses on hemodynamic influences during total intravenous anesthesia induction with propofol and remifentanil and endotracheal intubation (Euroanaesthesia 2025) - "We recorded hemodynamics [systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and heart rate (HR)], before injecting either ramosetron or normal saline, at loss of consciousness, at 1 min after rocuronium injection, before endotracheal intubation, and 1 min after endotracheal intubation. A high dose of ramosetron can be expected to reduce the degree of blood pressure drop that occurs during anesthesia induction and endotracheal intubation. However, further studies are needed on whether a high dose of ramosetron can satisfy the effectiveness of preventing PONV or drug injection pain simultaneously without clinically significant side effects."

Intubation • Anesthesia • Hypotension • Pain

The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. (PubMed, Am J Gastroenterol) - "Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation due to an AE when compared to rifaximin, the safest pharmacotherapy studied."

Journal • Retrospective data • Gastrointestinal Disorder

EVALUATING THE SAFETY OF PHARMACOTHERAPY FOR IRRITABLE BOWEL SYNDROME: A META-ANALYSIS (DDW 2025) - "AEs were more varied for tricyclics (indicated for IBS global symptoms); for example, compared to placebo the three most common AEs with associated risk increases were drowsiness (14%), dry mouth (12%), and weight gain (9%) for amitriptyline, dry mouth (22%), flushing (18%), and constipation (17%) for desipramine, and fatigue (15%), dry mouth (3%) and blurry vision (1.5%) for doxepin...The NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor (indicated for IBS-C) was 27 (p < 0.01), 53 (p = 0.59), 58 (p < 0.01), 59 (p = 0.03), and 17 (p <0.01) respectively. The NNH for alosetron and eluxadoline (indicated for IBS-D) was 16 (p < 0.01) and 32 (p < 0.01). Ramosetron and rifaximin (indicated for IBS-D) had a negative risk difference, with the rate of withdrawal due to AEs higher in the placebo arm, so NNH was a negative, although statistically insignificant, value... Tricyclics, alosetron, and tenapanor are associated with a higher..."

Retrospective data • Constipation • Fatigue • Gastrointestinal Disorder • Xerostomia

5-HT3 receptor antagonists for preventing postoperative nausea and vomiting after gynecological surgery: A systematic review and network meta-analysis. (PubMed, Int J Gynaecol Obstet) - "In gynecological surgery, palonosetron demonstrated superior efficacy to ondansetron. Granisetron seemed to be the most effective alternative to palonosetron in our study."

Clinical • Journal • Retrospective data • Review • Gynecology

Treatment of Irritable Bowel Syndrome with Predominant Diarrhea (PubMed, Korean J Gastroenterol) - "Pharmacological treatments include antidiarrheal agents, such as loperamide, which reduce stool frequency but have limited effects on pain relief. Antispasmodics, such as octylonium bromide and hyoscine butylbromide, alleviate abdominal pain by modulating intestinal motility. Rifaximin, a non-absorbable antibiotic, has shown efficacy in symptom reduction by altering the gut microbiota. Selective serotonin receptor antagonists, such as ramosetron, have benefits in symptom control, particularly in male patients...Personalized treatment approaches are essential because IBS-D presents a wide spectrum of symptoms. Clinicians should tailor therapeutic plans based on individual patient characteristics, balancing the benefits and risks of each intervention to optimize symptom control and improve the quality of life."

Journal • Review • Gastrointestinal Disorder • Immunology • Pain

Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study. (PubMed, J Pharm Health Care Sci) - "5-HT3RAs may prevent azacitidine-induced nausea and vomiting more effectively than metoclopramide."

Journal • Observational data • Retrospective data • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Physicochemical stability of mixtures of non-steroidal anti-inflammatory drugs such as ketorolac and diclofenac and antiemetics such as ondansetron and ramosetron: an in vitro study. (PubMed, Korean J Pain) - "Mixtures of ketorolac or diclofenac and ramosetron demonstrated physical and chemical stability for up to 2 hours, indicating that their concurrent use is feasible. Conversely, mixtures of ketorolac or diclofenac and ondansetron should be avoided due to the formation of crystals, even though the concentration of each drug remained stable."

Journal • Preclinical

Impact of basal infusion on postoperative nausea and vomiting in fentanyl-based intravenous patient-controlled analgesia: A randomized controlled trial. (PubMed, Medicine (Baltimore)) - "Fentanyl-based IV PCA without basal infusion resulted in less postoperative nausea and vomiting than IV PCA with basal infusion and maintained adequate analgesia. Basal infusion can be omitted to reduce postoperative nausea using IV PCA by applying an appropriate lock-out interval. Further research comparing variable PCA settings is warranted."

Clinical • Journal • Anesthesia • Gynecology • Pain

Unraveling a Rare Case: Diarrhea, Alopecia, and Polyposis. (PubMed, Gastroenterology) - No abstract available

Journal • Alopecia • Immunology

CYP2D6 genotype and associated 5-HT3 receptor antagonist outcomes: A systematic review and meta-analysis. (PubMed, Clin Transl Sci) - "5-hydroxytryptamine-3 (5-HT3) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. In this review, we confirm that CYP2D6 genotype impacts ondansetron response in a postoperative nausea and vomiting setting, which was supported by a meta-analysis. We also highlight the heterogeneity and limitations of included studies as well as provide future directions for pharmacogenomics research."

Clinical • Journal • Retrospective data • Review • Pediatrics

Pharmacological Strategies for Postdischarge Nausea and Vomiting: Evidence-based Review Update. (PubMed, J Perianesth Nurs) - "There is limited evidence on the efficacy of pharmacological agents in preventing PDNV. The scarcity of large-scale, clinical trials specifically focusing on PDNV restricts the ability to recommend prophylactic drug therapy for reducing its incidence."

Journal • Review

Cost-effectiveness of prophylactic ramosetron in the prevention of postoperative nausea and vomiting. (PubMed, PLoS One) - "The results demonstrated that prophylactic use of ramosetron compared to no antiemetic therapy is highly cost-effective to prevent PONV for patients undergoing surgery from both healthcare payer and societal perspectives. The cost effectiveness is the result of the decrease in the incidence of PONV and the direct treatment costs of severe PONV with improved patient quality of life."

Cost effectiveness • HEOR • Journal

Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study. (PubMed, Dose Response) - "The insoluble particles were in line with Chinese Pharmacopoeia. Our findings suggest that combinations of ramosetron hydrochloride with dexamethasone sodium phosphate in 0.9% sodium chloride injection remain stable for 14 days at 4°C and 48 h at 25°C when protected from light."

Journal • Chemotherapy-Induced Nausea and Vomiting

Effects of morroniside isolated from Cornus officinalis fruits on functional gastrointestinal disorders and gastric ulcer in mice. (PubMed, Fitoterapia) - "The dried fruits of Cornus officinalis (Cornaceae) are used in Kampo medicine (e.g. Hachimigan and Goshajinkigan) to treat senile osteoporosis, diabetes, gastric atony, frequent urination, and diarrhea/constipation associated with aging...officinalis extract, morroniside and 5-HT3 receptor antagonist (ramosetron) attenuated 5-HT-induced diarrhea...The results obtained herein suggest the potential of morroniside as an effective treatment for irritable bowel syndrome, such as diarrhea and functional dyspepsia (reductions in gastric emptying and small intestinal motility), caused by 5-HT. The present study suggests a role for morroniside in the regulation of elevations in CRF, ACTH, and corticosterone levels through hypothalamic-pituitary-adrenal axis activity induced by stress loading, such as a 5-HT treatment and/or HCl/EtOH stimulation."

Journal • Preclinical • Constipation • Diabetes • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Osteoporosis • Peptic Ulcer • Rheumatology

Dosing Strategy of Ramosetron to Prevent Postoperative Nausea and Vomiting and Development of Prediction Models Using Data Obtained From Randomized Controlled Trials: A Comparative Study. (PubMed, Clin Ther) - "The repeated administration of ramosetron did not reduce the incidence of PONV. The Apfel model had high sensitivity, however, its specificity and accuracy were lower than that in machine-learning-based models."

Journal

Evaluation of Cisplatin-Induced Acute Kidney Injury in Patients Co-Prescribed Serotonin Receptor Antagonists: A Retrospective Analysis. (PubMed, Kidney360) - "Nephrotoxicity continues to be a concern following cisplatin therapy. Given its emetogenic nature, use of antiemetic drugs such as 5-HT3RAs can lessen emesis and lower risk of kidney injury. This retrospective analysis supports use of any 5-HT3RAs to lower risk of AKI."

Journal • Retrospective data • Acute Kidney Injury • Nephrology • Oncology • Renal Disease